CERo Therapeutics Holdings (CERo Therapeutics Holdings) COGS-to-Revenue : 0.00 (As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings COGS-to-Revenue?

CERo Therapeutics Holdings's Cost of Goods Sold for the six months ended in Dec. 2022 was $0.00 Mil. Its Revenue for the six months ended in Dec. 2022 was $0.00 Mil.

CERo Therapeutics Holdings's COGS to Revenue for the six months ended in Dec. 2022 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. CERo Therapeutics Holdings's Gross Margin % for the six months ended in Dec. 2022 was N/A%.

CERo Therapeutics Holdings COGS-to-Revenue Historical Data

The historical data trend for CERo Therapeutics Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings COGS-to-Revenue Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

COGS-to-Revenue

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
COGS-to-Revenue	-	-

CERo Therapeutics Holdings COGS-to-Revenue Calculation

CERo Therapeutics Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

CERo Therapeutics Holdings's COGS to Revenue for the quarter that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

CERo Therapeutics Holdings (NAS:CERO) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

CERo Therapeutics Holdings's Gross Margin % for the six months ended in Dec. 2022 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

CERo Therapeutics Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024